TheProfitWatch

CRDF - Cardiff Oncology, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
2.02 0.01 (0.62%) 0.01 (0.5%) 0.01 (0.74%) 0.01 (0.74%) -0.05 (-2.35%) 0.07 (3.57%) --- -0.05 (-2.35%)

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.21
Diluted EPS:
-0.21
Basic P/E:
-9.6667
Diluted P/E:
-9.6667
RSI(14) 1m:
57.49
VWAP:
2.02
RVol:

Events

Period Kind Movement Occurred At

Related News